Jordi Remon

29PUBLICATIONS
152CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesPredictive and prognostic markersHealth economics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Jul 28, 2026
New Treatment Strategies for Rare Genomic Alterations: EGFR Exon 20 Insertions and HER2-Deregulated Lung Cancer.

|Apr 08, 2026
Less Is More, But Me-Too Should Not Be the Strategy for Lung Cancer Treatment in 2026.

Martina Bortolot, Stephanie P L Saw, Erica Pietroluongo

|Apr 07, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.

Arianna Marinello, Julia K Rotow, Meghanne Lomibao

|Jan 22, 2026
BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung Cancer.

Jordi Remon, Tina Cascone, Solange Peters

|Dec 12, 2025
Author Correction: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial.

Oscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia

|Oct 09, 2025
Unresectable stage III non-small-cell lung cancer: state of the art and challenges.

Jordi Remon, Antonin Levy, Romane Gille

Pageof 5

Frequent Collaborators

7 joint publications

Lizza Hendriks

7 joint publications

Benjamin Besse

4 joint publications

Mihaela Aldea

3 joint publications

Lodovica Zullo